Innoviva’s Stock Climbs Slightly, But Investors Should Scrutinize Its Real Growth Potential
Innoviva shares slip 0.95%, hovering near $20.91, as investors question the biotech firm’s lack of product pipeline and weak momentum amid market turbulence.
3 minutes to read